The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients
with transitional cell carcinoma of the urothelium which failed or progressed after two lines
of chemotherapy